Objective To investigate the effect of trimetazidine combined with levocanidine on the heart function of patients with ischemic cardiomyopathy with heart failure.Methods Eighty-six patients with ischemic cardiomyopathy with heart failure admitted to the cardiology department of a hospital in Nanyang from May 2017 to May 2020 were selected for the study and divided into a control group（43 cases） and an observation group（43 cases） according to different treatment modalities.The control group was treated with levocanidine

and the observation group was treated with trimetazidine combined with levocanidine

and both groups were treated for 3 months.The clinical efficacy

cardiac output（CO）

stroke volume（SV） and left ventricular ejection fraction（LVEF）

QT dispersion（QTd）

corrected QT dispersion（QTcd） and QRS of the patients in the two groups were compared before and after treatment.Results The total effective rate of treatment for patients in the control group was 83.72%

which was lower than 97.67% in the observation group

and the difference was statistically significant（χ~2= 5.075

P= 0.024）.Before treatment

there was no statistically significant difference between the indices of heart function in the 2 groups of patients（P>0.05）.After treatment

CO

SV and LVEF of patients in the observation group were higher than those before treatment and significantly higher than those in the control group

and the differences were all statistically significant（P<0.05）;QTd

QTcd and QRS were all lower than before treatment and significantly lower in the observation group than in the control group

and the differences were all statistically significant（P<0.05）.Conclusion The improvement of heart function in patients with ischemic cardiomyopathy with heart failure by trimetazidine combined with levocanidine is obvious

and the therapy is worthy of clinical promotion.